Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Education and guidance program for Eliquis adherence in non-valvular atrial fibrillation
NL-OMON38431Phase 4Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Correct execution of apixaban dosing regimen at 24 weeks. Planned start Oct 2013; status: withdrawn.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON38431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38431.